@Article{Weiss2009,
  author    = {Weiss, Angelina and Preston, Thomas C. and Popov, Jesse and Li, Qifeng and Wu, Sherry and Chou, Keng C. and Burt, Helen M. and Bally, Marcel B. and Signorell, Ruth},
  journal   = {The Journal of Physical Chemistry C},
  title     = {Selective {Recognition} of {Rituximab}-{Functionalized} {Gold} {Nanoparticles} by {Lymphoma} {Cells} {Studied} with {3D} {Imaging}},
  year      = {2009},
  issn      = {1932-7447},
  month     = nov,
  number    = {47},
  pages     = {20252--20258},
  volume    = {113},
  abstract  = {Several types of multivalent therapeutic antibody constructs have recently been described which exhibit an increased efficacy compared to free, bivalent antibody. For example, it has been shown that rituximab-coupled liposomes (devoid of encapsulated drug) show a stronger response than equal amounts of monomeric rituximab, supposedly due to the ability of the multivalent complex to hyper-cross-link its target in the plasma membrane. We sought to create a new type of multivalent antibody construct using gold nanoparticles, where rituximab is bound to the particle surface through a strong covalent bond. In the present study, rituximab-conjugated gold particles have been prepared with the aim of identifying suitable formulations for use in studies assessing the therapeutic potential of these novel formulations. Different types of rituximab-conjugated particles are prepared and characterized. The size of the particles, as well as the type of functionalization, is varied. In vitro studies with CD-20 positive human mantle cell lymphoma cells and CD-20 negative breast cancer cells combined with three-dimensional (3D) imaging allowed us to select an optimized rituximab-gold system for further studies. Selective recognition of these rituximab nanocarriers by lymphoma cells is demonstrated.},
  doi       = {10.1021/jp907423z},
  file      = {Full Text PDF:https\://pubs.acs.org/doi/pdf/10.1021/jp907423z:application/pdf;ACS Full Text Snapshot:https\://pubs.acs.org/doi/full/10.1021/jp907423z:text/html},
  publisher = {American Chemical Society},
  url       = {https://doi.org/10.1021/jp907423z},
  urldate   = {2020-06-19TZ},
}

{"_id":"W3JdwkxFjhSrgSQeA","bibbaseid":"weiss-preston-popov-li-wu-chou-burt-bally-etal-selectiverecognitionofrituximabfunctionalizedgoldnanoparticlesbylymphomacellsstudiedwith3dimaging-2009","authorIDs":[],"author_short":["Weiss, A.","Preston, T. C.","Popov, J.","Li, Q.","Wu, S.","Chou, K. C.","Burt, H. M.","Bally, M. B.","Signorell, R."],"bibdata":{"bibtype":"article","type":"article","author":[{"propositions":[],"lastnames":["Weiss"],"firstnames":["Angelina"],"suffixes":[]},{"propositions":[],"lastnames":["Preston"],"firstnames":["Thomas","C."],"suffixes":[]},{"propositions":[],"lastnames":["Popov"],"firstnames":["Jesse"],"suffixes":[]},{"propositions":[],"lastnames":["Li"],"firstnames":["Qifeng"],"suffixes":[]},{"propositions":[],"lastnames":["Wu"],"firstnames":["Sherry"],"suffixes":[]},{"propositions":[],"lastnames":["Chou"],"firstnames":["Keng","C."],"suffixes":[]},{"propositions":[],"lastnames":["Burt"],"firstnames":["Helen","M."],"suffixes":[]},{"propositions":[],"lastnames":["Bally"],"firstnames":["Marcel","B."],"suffixes":[]},{"propositions":[],"lastnames":["Signorell"],"firstnames":["Ruth"],"suffixes":[]}],"journal":"The Journal of Physical Chemistry C","title":"Selective Recognition of Rituximab-Functionalized Gold Nanoparticles by Lymphoma Cells Studied with 3D Imaging","year":"2009","issn":"1932-7447","month":"November","number":"47","pages":"20252–20258","volume":"113","abstract":"Several types of multivalent therapeutic antibody constructs have recently been described which exhibit an increased efficacy compared to free, bivalent antibody. For example, it has been shown that rituximab-coupled liposomes (devoid of encapsulated drug) show a stronger response than equal amounts of monomeric rituximab, supposedly due to the ability of the multivalent complex to hyper-cross-link its target in the plasma membrane. We sought to create a new type of multivalent antibody construct using gold nanoparticles, where rituximab is bound to the particle surface through a strong covalent bond. In the present study, rituximab-conjugated gold particles have been prepared with the aim of identifying suitable formulations for use in studies assessing the therapeutic potential of these novel formulations. Different types of rituximab-conjugated particles are prepared and characterized. The size of the particles, as well as the type of functionalization, is varied. In vitro studies with CD-20 positive human mantle cell lymphoma cells and CD-20 negative breast cancer cells combined with three-dimensional (3D) imaging allowed us to select an optimized rituximab-gold system for further studies. Selective recognition of these rituximab nanocarriers by lymphoma cells is demonstrated.","doi":"10.1021/jp907423z","file":"Full Text PDF:https\\://pubs.acs.org/doi/pdf/10.1021/jp907423z:application/pdf;ACS Full Text Snapshot:https\\://pubs.acs.org/doi/full/10.1021/jp907423z:text/html","publisher":"American Chemical Society","url":"https://doi.org/10.1021/jp907423z","urldate":"2020-06-19TZ","bibtex":"@Article{Weiss2009,\r\n author = {Weiss, Angelina and Preston, Thomas C. and Popov, Jesse and Li, Qifeng and Wu, Sherry and Chou, Keng C. and Burt, Helen M. and Bally, Marcel B. and Signorell, Ruth},\r\n journal = {The Journal of Physical Chemistry C},\r\n title = {Selective {Recognition} of {Rituximab}-{Functionalized} {Gold} {Nanoparticles} by {Lymphoma} {Cells} {Studied} with {3D} {Imaging}},\r\n year = {2009},\r\n issn = {1932-7447},\r\n month = nov,\r\n number = {47},\r\n pages = {20252--20258},\r\n volume = {113},\r\n abstract = {Several types of multivalent therapeutic antibody constructs have recently been described which exhibit an increased efficacy compared to free, bivalent antibody. For example, it has been shown that rituximab-coupled liposomes (devoid of encapsulated drug) show a stronger response than equal amounts of monomeric rituximab, supposedly due to the ability of the multivalent complex to hyper-cross-link its target in the plasma membrane. We sought to create a new type of multivalent antibody construct using gold nanoparticles, where rituximab is bound to the particle surface through a strong covalent bond. In the present study, rituximab-conjugated gold particles have been prepared with the aim of identifying suitable formulations for use in studies assessing the therapeutic potential of these novel formulations. Different types of rituximab-conjugated particles are prepared and characterized. The size of the particles, as well as the type of functionalization, is varied. In vitro studies with CD-20 positive human mantle cell lymphoma cells and CD-20 negative breast cancer cells combined with three-dimensional (3D) imaging allowed us to select an optimized rituximab-gold system for further studies. Selective recognition of these rituximab nanocarriers by lymphoma cells is demonstrated.},\r\n doi = {10.1021/jp907423z},\r\n file = {Full Text PDF:https\\://pubs.acs.org/doi/pdf/10.1021/jp907423z:application/pdf;ACS Full Text Snapshot:https\\://pubs.acs.org/doi/full/10.1021/jp907423z:text/html},\r\n publisher = {American Chemical Society},\r\n url = {https://doi.org/10.1021/jp907423z},\r\n urldate = {2020-06-19TZ},\r\n}\r\n\r\n","author_short":["Weiss, A.","Preston, T. C.","Popov, J.","Li, Q.","Wu, S.","Chou, K. C.","Burt, H. M.","Bally, M. B.","Signorell, R."],"key":"Weiss2009","id":"Weiss2009","bibbaseid":"weiss-preston-popov-li-wu-chou-burt-bally-etal-selectiverecognitionofrituximabfunctionalizedgoldnanoparticlesbylymphomacellsstudiedwith3dimaging-2009","role":"author","urls":{"Paper":"https://doi.org/10.1021/jp907423z"},"downloads":0,"html":""},"bibtype":"article","biburl":"https://lasir.ca/wp-content/uploads/LASIR-biblio.bib","creationDate":"2020-07-24T08:03:38.809Z","downloads":0,"keywords":[],"search_terms":["selective","recognition","rituximab","functionalized","gold","nanoparticles","lymphoma","cells","studied","imaging","weiss","preston","popov","li","wu","chou","burt","bally","signorell"],"title":"Selective Recognition of Rituximab-Functionalized Gold Nanoparticles by Lymphoma Cells Studied with 3D Imaging","year":2009,"dataSources":["EwrBFmJGvAFRq9Qaq"]}